Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study

NCT02993107 is registered in ClinicalTrials.gov with Aimmune Therapeutics, Inc. as lead sponsor.

NCT NCT02993107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02993107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study
Lead sponsor
Aimmune Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 29, 2016
Completion date
May 31, 2019
Enrollment
388 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

peanut allergy